Hospital

The phase 3 DeLLphi-305 trial found that the first-line maintenance therapy improved overall survival in extensive-stage small cell lung cancer (ES-SCLC) compared with durvalumab alone.

A 5-level model for classifying AI-enabled pharmacy systems may help health systems advance to new levels of pharmacy autonomy.

Preclinical research identifies tumor-secreted PRDX1 as a potential “redox checkpoint” that suppresses T-cell activity and may contribute to resistance to immune checkpoint inhibitors.

In an interview with Pharmacy Times, Claudia R. Morris, MD, lead investigator and author of the phase 3 STArT trial and a pediatric emergency medicine physician at Children’s Healthcare of Atlanta, discussed the need for more meaningful end points in sickle cell pain trials, future research targeting acute chest syndrome, and how pharmacists can improve the collection of opioid-use data.

Titilola M. Afolabi discusses how gaps in pediatric-specific evidence shaped her path into research and highlights the interdisciplinary studies that have defined her career.

Clear governance, appropriate oversight, and alignment among technology, policy, and payment will be essential.

A single-center study found similar 12-month total weight loss whether or not patients used a glucagon-like peptide-1 (GLP-1) receptor agonist before surgery.

Long-lived monocyte-derived cells in the lung help sustain tissue-resident memory T cells after influenza infection, and researchers say the discovery could inform more effective nasal flu vaccines.

A prospective multicenter study found high response rates with first-line obinutuzumab plus bendamustine across several indolent B-cell lymphoma subtypes, although short follow-up and the absence of a comparator limit conclusions about long-term benefit.

Blood Cancer Awareness Month highlights types of blood cancer and how pharmacists flag multiple myeloma symptoms early, speeding referral and care.

A prespecified analysis found the PCSK9 inhibitor reduced total events 20% in high-risk patients with no prior heart attack or stroke.

In an interview with Pharmacy Times, Claudia R. Morris, MD, lead investigator and author of the phase 3 STArT trial and a pediatric emergency medicine physician at Children’s Healthcare of Atlanta, discussed how treatment timing and patient heterogeneity may inform the design of future sickle cell pain trials.

Independent pharmacies should build documentation, watch rulemaking, and press for transparency terms in every contract renewal.

Zilganersen, an antisense oligonucleotide targeting glial fibrillary acidic protein, is cleared for pediatric and adult patients across all ages.

Trial investigator Claudia R. Morris, MD, said substantial variation in pain phenotypes, treatment practices, and trial end points may offer broader lessons for future acute sickle cell disease research.

In an interview with Pharmacy Times, Claudia R. Morris, MD, lead investigator and author of the phase 3 STArT trial and a pediatric emergency medicine physician at Children’s Healthcare of Atlanta, discussed how patient history and institutional pain-management practices may influence time to crisis resolution and how care teams, including pharmacists, can help standardize treatment.

Time-to-vaccination data from a large diabetes cohort reveal delayed, incomplete uptake of pneumococcal vaccination, with age and citizenship emerging as the strongest predictors.

The phase 3 findings support MR-107A-02's potential as a nonopioid option for certain patients with moderate to severe acute pain.

Melissa Seifert, PharmD, of UPMC Health Plan, explains how managed care pharmacists guide DMT selection and address adherence barriers in patients with MS.

A clinical pharmacy specialist at UPMC Health Plan discusses how pharmacists help select disease-modifying therapies, address adherence barriers, and coordinate whole-person care for those with MS.

In an interview with Pharmacy Times, Claudia R. Morris, MD, lead investigator and author of the phase 3 STArT trial, discusses why intravenous arginine did not shorten time to crisis resolution and how institutional variation, pain heterogeneity, shorter hospital stays, and treatment timing may have influenced the findings.

Glucagon-like peptide-1 (GLP-1) and GIP/GLP-1 agents are just the start: amylin- and glucagon-based mono-, dual-, and tri-therapies are on the horizon.

A subsequent dispute between state and federal officials over the deaths' classification has thrust the state into the center of a national vaccine policy fight.

This FAQ describes what oncology pharmacists should know ahead of Gynecologic Cancer Awareness Month in September.

In an interview with Pharmacy Times, Claudia R. Morris, MD, lead author of the phase 3 STArT trial and professor of pediatrics and emergency medicine at Emory University School of Medicine, discusses findings from the phase 3 STArT trial of intravenous arginine for acute sickle cell pain, limitations of time to crisis resolution as a clinical trial end point, and opportunities for pharmacists to improve opioid-use data collection.

August 2026 brought major oncology advances, including new FDA approvals and pivotal phase 3 data that expanded targeted, immune-based, and personalized treatment strategies.

August 2026 brought first-in-class approvals in multiple myeloma, warm autoimmune hemolytic anemia, and polycythemia vera alongside important findings involving bispecific antibodies, sickle cell pain, and infection risk.

The approval makes ustekinumab the first non-TNF-alpha monoclonal antibody available for both major forms of pediatric inflammatory bowel disease (IBD).